Cancer Family
Female Reproductive System Adnexal Neoplasm
CI-CAN-00000180Explore in graph →
Non-malignant765 active trials5 approved drugs94 evidence items
- NCIt
- C212117
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000180Explore in graph →
Clinical trials
3,476 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01689636 | Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients | completed | Phase 1 | 8 | EndocyteINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01689714 | Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma | completed | Phase 2 | 16 | EndocyteINDUSTRY | 0 | Jun 22, 2023 | clinicaltrials |
| NCT03563781 |
| SEntine Lymph Node in earLY Ovarian Cancer (SELLY)(SELLY) |
| completed |
| N/A |
| 176 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER |
| 1 |
| Jun 22, 2023 |
| clinicaltrials |
| NCT00001503 | Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease | completed | — | 1,031 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)(ARIEL2) | completed | Phase 2 | 491 | pharmaand GmbHINDUSTRY | 6 | Jun 12, 2023 | clinicaltrials |
| NCT01482715 | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | completed | Phase 1 / Phase 2 | 136 | pharmaand GmbHINDUSTRY | 5 | Jun 9, 2023 | clinicaltrials |
| NCT01968213 | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)(ARIEL3) | completed | Phase 3 | 564 | pharmaand GmbHINDUSTRY | 11 | Jun 9, 2023 | clinicaltrials |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | completed | Phase 3 | 349 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT04902144 | Clinical Outcomes for Offering Genetic Testing in a Tiered Approach | completed | N/A | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT02781272 | Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.(EMBER) | completed | — | 200 | Angle plcINDUSTRY | 1 | Jun 5, 2023 | clinicaltrials |
| NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer | completed | Phase 3 | 596 | Tesaro, Inc.INDUSTRY | 15 | Jun 2, 2023 | clinicaltrials |
| NCT02063464 | Blood Collection From People With Ovarian Cancer | completed | — | 85 | National Cancer Institute (NCI)NIH | 1 | May 24, 2023 | clinicaltrials |
| NCT05868889 | Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD | completed | — | 43 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT03657043 | A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) | completed | Phase 2 | 98 | Seagen Inc.INDUSTRY | 6 | May 6, 2023 | clinicaltrials |
| NCT02898207 | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 26, 2023 | clinicaltrials |
| NCT00538031 | Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 52 | City of Hope Medical CenterOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05751629 | Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer(COHORT-A) | completed | Phase 2 | 41 | Tesaro, Inc.INDUSTRY | 1 | Apr 21, 2023 | clinicaltrials |
| NCT02258165 | Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer(IMAGE) | completed | — | 84 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Apr 18, 2023 | clinicaltrials |
| NCT02737787 | A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer | completed | Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT03073525 | A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers | completed | Phase 2 | 25 | Gradalis, Inc.INDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04630769 | FT516 and IL2 With Enoblituzumab for Ovarian Cancer | completed | Phase 1 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03507452 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | completed | Phase 1 | 36 | BayerINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT04041128 | PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer | completed | Early Phase 1 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT02659384 | Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer | completed | Phase 2 | 122 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Mar 14, 2023 | clinicaltrials |
| NCT02227654 | Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors | completed | N/A | 179 | Frederick R. Ueland, M.D.OTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT00565903 | Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome(PPB) | completed | — | 1,247 | Ashley HillOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03287674 | TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer | completed | Phase 1 / Phase 2 | 7 | Inge Marie SvaneOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03689192 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | completed | Phase 1 | 13 | Herlev HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03756818 | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT02166905 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | completed | Phase 1 / Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT03464201 | Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study(GREKO III) | completed | Phase 2 | 16 | Grupo Español de Tumores Huérfanos e InfrecuentesOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05734911 | Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study | completed | — | 199 | Zhongda HospitalOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03038100 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(IMagyn050) | completed | Phase 3 | 1,301 | Hoffmann-La RocheINDUSTRY | 22 | Feb 17, 2023 | clinicaltrials |
| NCT03639246 | Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | completed | Phase 1 | 53 | Aravive, Inc.INDUSTRY | 1 | Feb 13, 2023 | clinicaltrials |
| NCT03004391 | Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125 | completed | — | 25 | Vejle HospitalOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT03161132 | Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin(ROLANDO) | completed | Phase 2 | 32 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies(SIGN) | completed | Phase 2 | 116 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jan 26, 2023 | clinicaltrials |
| NCT02973750 | Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer | completed | — | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT04753216 | Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 3 | Northwestern UniversityOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02489058 | A Study of Long-Term Responders on Olaparib(OLALA) | completed | — | 118 | University Health Network, TorontoOTHER | 5 | Jan 10, 2023 | clinicaltrials |
| NCT03398655 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)(OVAL) | completed | Phase 3 | 408 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT02963831 | A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | completed | Phase 1 / Phase 2 | 67 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT02595281 | HE4 as a Relapse Biomarker in Ovarian Cancers(PRONOV4IR) | completed | N/A | 90 | Institut de Cancérologie de LorraineOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT02013492 | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Early Phase 1 | 1 | William CarsonOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer(TOPACIO) | completed | Phase 1 / Phase 2 | 122 | Tesaro, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jun 22, 2023source: clinicaltrials